DNDN - Dendreon Corporation (NASDAQ:DNDN)
- Creatore Discussione stegigio
- Data di inizio
-
Due nuove obbligazioni Societe Generale, in Euro e in Dollaro USA
Societe Generale porta sul segmento Bond-X (EuroTLX) di Borsa Italiana due obbligazioni, una in EUR e una in USD, a tasso fisso decrescente con durata massima di 15 anni e possibilità di rimborso anticipato annuale a discrezione dell’Emittente.
Per continuare a leggere visita questo LINK
- Stato
- Registrato
- 24/3/10
- Messaggi
- 11.678
- Punti reazioni
- 152
ci mettiamo sulla trend o sul doppio minimo?
Allegati
UNICOMISTERO
Omnia munda mundis
- Registrato
- 29/12/06
- Messaggi
- 38.059
- Punti reazioni
- 1.177
simoncinimauro
Utente Registrato
- Registrato
- 25/8/07
- Messaggi
- 474
- Punti reazioni
- 13
Dendreon again tumbles on Provenge outlook - Yahoo! Finance
I RICAVI DEL PROVENGE NON SONO POI COSI ESALTANTI
SunTzuPin
Utente Registrato
- Registrato
- 14/11/09
- Messaggi
- 797
- Punti reazioni
- 46
Kyro,
La penso come Te,
Si potrebbe vedere ancora verso quota 2.6-3 dollari di questo passo
- Registrato
- 14/10/11
- Messaggi
- 57
- Punti reazioni
- 5
Ciao Carlo64.
Gran titolo. Infinite possibilità. Ma come bio puo' perdere ancora parecchio
Dendreon Corporation Stock Chart | DNDN Interactive Chart - Yahoo! Finance
Olaaaaaaa
- Registrato
- 14/10/11
- Messaggi
- 57
- Punti reazioni
- 5
Mah. Puo' darsi. Io aspetterei anche un po' sotto. Magaro 4,02$. Ma non sono un guru
Olaaaaaaaaa
kyro
Utente Registrato
- Registrato
- 17/2/04
- Messaggi
- 1.974
- Punti reazioni
- 99
Anche a 3$ sarà rischiosa.
Il CEO ha dichiarato che per generare un cash flow positivo dovrebbe fatturare almeno 500M all'anno. A 93.000$ per ciclo significa circa 5000 pazienti da trattare e secondo la trimestrale sono a circa 700 x quarter.
Ieri la Medivation è salita del 140% sulla news che hanno interrotto il trial del loro farmaco contro il cancro alla prostata per darlo anche a quelli del braccio di controllo visto gli ottimi risultati. Diminuisce il rischio di morte del 37% e allunga la vita in media di 5 mesi contro i 30gg. del Provenge.
Che faranno i 5000 pazienti che dovrebbe trovare il provenge quando vedranno questi risultati? e tenendo presente che il provenge è anche l'unico farmaco della DNDN i guai si stanno facendo veramente seri.
Alfonso Rubini
Utente Registrato
- Registrato
- 10/12/02
- Messaggi
- 559
- Punti reazioni
- 41
A prescindere da tutto..
DNDN rappresenta una pietra miliare nell'approcio alla lotta al cancro.Nel 2009 ero dentro a circa 3$, poi uscì l'approvazione dell FDA e vendetti tutto intorno agli 11 con ottimo gain.Il titolo continuò a crescere fino a circa 20 x poi arrivare a 50$ e stabilizzarsi sui 40, quota che mi sembrava troppo alta.Ripeto, visto l'approccio rivoluzionario alla lotta al tumore dovrebbe stare sui 20$ a prescindere dalle vendite:diciamo un "valore aggiunto" nel rispetto del rivoluzionario metodo nel combattere il male del secolo.IMHO
DNDN rappresenta una pietra miliare nell'approcio alla lotta al cancro.Nel 2009 ero dentro a circa 3$, poi uscì l'approvazione dell FDA e vendetti tutto intorno agli 11 con ottimo gain.Il titolo continuò a crescere fino a circa 20 x poi arrivare a 50$ e stabilizzarsi sui 40, quota che mi sembrava troppo alta.Ripeto, visto l'approccio rivoluzionario alla lotta al tumore dovrebbe stare sui 20$ a prescindere dalle vendite:diciamo un "valore aggiunto" nel rispetto del rivoluzionario metodo nel combattere il male del secolo.IMHO
Alfonso Rubini
Utente Registrato
- Registrato
- 10/12/02
- Messaggi
- 559
- Punti reazioni
- 41
che stronz@ta... in borsa dell'etica non gliene frega niente a nessuno
Non parlo di etica, ma di (definiamolo così)..GLAMOUR....
Se AAPL capitalizza 400B $ , una parte lo deve a questo
Picchio99
So Burloni
- Registrato
- 4/9/02
- Messaggi
- 1.050
- Punti reazioni
- 77
ottima notizia adesso da monitorare
LINK Dendreon Announces Fourth Quarter Revenues and Update on Commercialization - Yahoo! Finance
SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (Nasdaq: DNDN - News) today announced revenue for the fourth quarter ended December 31, 2011, reporting gross product revenue of approximately $82 million. This represents approximately 25% growth over the third quarter ended September 30, 2011, and approximately 230% growth compared to the fourth quarter ended December 31, 2010. In addition, Dendreon reported full-year gross revenues from PROVENGE® (sipuleucel-T) sales of approximately $228 million.
“We are pleased with the progress we have made in the launch of PROVENGE, which – based on its first full year of revenues – places it as one of the top 10 product launches in oncology,” said Mitchell H. Gold, MD, president and chief executive officer.
In addition, Dendreon provided the following updates:
At the end of the fourth quarter, completed in-servicing for more than 840 total sites, of which:
More than 590 sites have infused PROVENGE, which represents the greatest growth in infusing sites quarter over quarter; and
Approximately 615 sites have either infused the product or have their patients scheduled for their first PROVENGE regimen.
Improved PROVENGE reimbursement landscape for customers and patients:
Reported average time to payment is less than 30 days for physicians, which is better than industry standard, reflecting an improved reimbursement landscape due to a national coverage decision and activation of a Q-code that accelerates electronic adjudication of claims.
The Centers for Medicare and Medicaid Services (CMS) updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE. With this decision, the coverage of PROVENGE is now consistent with all other infused biologics.
A recent analysis suggests that approximately 75% of patients had minimal or no out-of-pocket costs for PROVENGE.
“Given our results for the past two quarters, physician and patient interest in PROVENGE clearly continues to grow. We believe that the improved reimbursement landscape, along with our improved sales execution and physician education initiatives, are contributing to the increased use of PROVENGE in the community urology and oncology settings,” said Mitchell H. Gold, MD, president and chief executive officer. “We had a strong fourth quarter that exceeded our expectations. As we look to 2012, we expect modest quarter-over-quarter growth while we focus on bringing additional clinics on board and converting them into steady prescribers.”
“Importantly, we have sufficient cash-on-hand to meet our needs, and our focus operationally for 2012 is to reduce COGS across our manufacturing facilities to more efficiently produce PROVENGE for as many patients as possible,” said Gregory T. Schiffman, executive vice president and chief financial officer.
LINK Dendreon Announces Fourth Quarter Revenues and Update on Commercialization - Yahoo! Finance
SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (Nasdaq: DNDN - News) today announced revenue for the fourth quarter ended December 31, 2011, reporting gross product revenue of approximately $82 million. This represents approximately 25% growth over the third quarter ended September 30, 2011, and approximately 230% growth compared to the fourth quarter ended December 31, 2010. In addition, Dendreon reported full-year gross revenues from PROVENGE® (sipuleucel-T) sales of approximately $228 million.
“We are pleased with the progress we have made in the launch of PROVENGE, which – based on its first full year of revenues – places it as one of the top 10 product launches in oncology,” said Mitchell H. Gold, MD, president and chief executive officer.
In addition, Dendreon provided the following updates:
At the end of the fourth quarter, completed in-servicing for more than 840 total sites, of which:
More than 590 sites have infused PROVENGE, which represents the greatest growth in infusing sites quarter over quarter; and
Approximately 615 sites have either infused the product or have their patients scheduled for their first PROVENGE regimen.
Improved PROVENGE reimbursement landscape for customers and patients:
Reported average time to payment is less than 30 days for physicians, which is better than industry standard, reflecting an improved reimbursement landscape due to a national coverage decision and activation of a Q-code that accelerates electronic adjudication of claims.
The Centers for Medicare and Medicaid Services (CMS) updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE. With this decision, the coverage of PROVENGE is now consistent with all other infused biologics.
A recent analysis suggests that approximately 75% of patients had minimal or no out-of-pocket costs for PROVENGE.
“Given our results for the past two quarters, physician and patient interest in PROVENGE clearly continues to grow. We believe that the improved reimbursement landscape, along with our improved sales execution and physician education initiatives, are contributing to the increased use of PROVENGE in the community urology and oncology settings,” said Mitchell H. Gold, MD, president and chief executive officer. “We had a strong fourth quarter that exceeded our expectations. As we look to 2012, we expect modest quarter-over-quarter growth while we focus on bringing additional clinics on board and converting them into steady prescribers.”
“Importantly, we have sufficient cash-on-hand to meet our needs, and our focus operationally for 2012 is to reduce COGS across our manufacturing facilities to more efficiently produce PROVENGE for as many patients as possible,” said Gregory T. Schiffman, executive vice president and chief financial officer.
- Stato